FDA’s DTC Coupon Study Triggers First Amendment Objections From PhRMA
Executive SummaryFDA’s third attempt at studying the effects of coupons in direct-to-consumer print advertising triggers First Amendment concerns and raises the specter of regulatory restrictions based upon “potential deception,” according to the Pharmaceutical Research and Manufacturers of America.
You may also be interested in...
FDA to assess whether claims such as '#1 prescribed' affect consumer views of drug product; project to cost $529,742. Chart notes price tag for 18 other DTC studies.
The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.